Frank D. Lee Cashes Out $24.1 Million As Viatris Completes Pacira Takeover
The Pacira chief executive's entire reported share stake became cash-payment rights, alongside the cancellation of 692,512 options.
Frank D. Lee, chief executive of Pacira BioSciences, which develops and sells non-opioid pain treatments, cashed out $24.1 million in shares Tuesday through its completed merger with Viatris. His SEC insider-trading filing reported zero Pacira shares afterward, with the company now wholly owned by Viatris.
Lee's Shares Become Cash Rights
Lee's disposition covered 660,830.841 shares at the merger price of $36.50 each. The transaction converted his entire reported pre-merger share stake into rights to cash payments, subject to tax withholding.
The share total included restricted stock units, awards that entitle recipients to shares. Both vested and unvested awards were canceled, with their cash value determined by the number of shares covered and the $36.50 deal price.
Pacira and Viatris agreed to the acquisition on October 8, 2026. Viatris' acquisition subsidiary, Peach Purchaser Sub, completed a cash tender offer to buy all outstanding Pacira shares, then merged into Pacira on Tuesday.
Options Get A Separate Payout Formula
Lee also reported 692,512 canceled stock options carrying a $32.07 exercise price—the amount required to buy each underlying share. The merger terms gave those options cash-payment rights based on the difference between that price and the $36.50 offer price, subject to withholding.
The agreement applied that formula to vested and unvested options alike. Options with exercise prices equal to or above the offer price were canceled without payment.
Pacira shares closed at $36.48 on Tuesday, compared with the merger's $36.50 cash price. The shares were up 41% this year as of Monday's close.
EXPAREL Anchors Pacira's Pain Business
Pacira's business centers on three commercial products. EXPAREL, a long-acting local anesthetic injection approved for postsurgical pain, generated $575.1 million in sales in 2025, or 79% of total revenue.
ZILRETTA, an extended-release steroid injection for knee pain from osteoarthritis, had 2025 sales of $116.6 million. Sales of iovera, a handheld device that relieves pain by cooling a targeted nerve without drugs, were $24.2 million.
The Brisbane, California-based company is also developing PCRX-201, a gene therapy for knee osteoarthritis in mid-stage trials.
The merger leaves Lee with cash-payment rights for his reported shares and eligible options, and Viatris with ownership of Pacira's pain-treatment business.
Sources
- Form 4 — Frank D. Lee (PCRX) — SEC EDGAR